Friday, 23 October 2026European Markets

RALLYE Stock Was 16.58% Up Today

Loading stream...

(vianews) - the market ended the session with rallye (ral.pa) rising 16.58% to €0.32 on tuesday while cac 40 dropped 0.39% to €6,986.23.

rallye's last close was €0.27, 91.67% below its 52-week high of €3.30.

about rallye

rallye sa, together with its subsidiaries, engages in the food and non-food e-commerce retailing business in france and internationally. the company operates in two segments, food and general retailing, and holdings and other activities. it operates hypermarkets, supermarkets, and convenience stores. the company conducts its retailing activities in france primarily under the casino, monoprix, and franprix banners; food retail activities in brazil, colombia, uruguay, and argentina mainly under the gpa food banners, éxito, disco-devoto, and libertad banners; and e-commerce comprising cdiscount and the cnova n.v. holding company businesses. it is also involved in the financial investment, property development, and energy related activities. the company was founded in 1925 and is headquartered in paris, france. rallye sa operates as a subsidiary of foncière euris sa.

earnings per share

as for profitability, rallye has a trailing twelve months eps of €-12.91.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -71.26%.

volatility

rallye's last week, last month's, and last quarter's current intraday variation average was a positive 31.57%, a negative 0.83%, and a positive 7.31%.

rallye's highest amplitude of average volatility was 31.57% (last week), 8.81% (last month), and 7.31% (last quarter).

more news about rallye (ral.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Crunch: Late-Stage Readouts and Regulatory Milestones Converge on the Ivonescimab PDUFA Date
October 2026 is dense with clinical and regulatory news. Phase 3 trials hit primary endpoints (ALOFT-IPF, RESTORE-3), long-term data came out (MIUDELLA at 6 years, QUILT-3.032), and the FDA accepted Roche's vamikibart BLA. Scholar Rock resubmitted its apitegromab MAA to the EMA. The next catalysts are ESMO 2026 (Oct 23) and the Nov 14 FDA PDUFA date for ivonescimab, followed by Maritime-1 primary completion in January 2027. The speculative QAIAx items (QIII pilot, microcities patent) are a weak, tangential thread with little financial substance.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,426 source documents archived
Query this data → isubstrate.com